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Objective: To report the methodology and summary data of the Health Outcomes
and Lifestyle In a Sample of people with Multiple sclerosis (HOLISM) longitudinal and
validation cohorts. We report (1) data on participation, socio-demographics, disease
characteristics, medication use, modifiable lifestyle risk factor exposures, and health
outcomes of the HOLISM longitudinal cohort 2.5-years post enrolment; (2) attrition at
this 2.5-year wave; and (3) baseline characteristics of the associated HOLISM validation
cohort.
Methods: The HOLISM longitudinal study recruited people internationally with
self-reported diagnosed multiple sclerosis (MS) through web 2.0 platforms and MS
society newsletters. Participants, first recruited in 2012, were invited 2.5-years later
to participate in a follow-up survey. At both time points, participants completed
a comprehensive online questionnaire of socio-demographics, modifiable lifestyle
exposures, and health outcomes using validated and researcher-designed tools. The
same methodology was used to recruit a new sample: the HOLISM validation cohort.
Characteristics were explored using summary measures.
Results: Of 2,466 people with MS at baseline, 1,401 (56.8%) provided data at
2.5-year follow-up. Attrition was high, likely due to limited amount of contact information
collected at baseline. Completion of the 2.5-year wave was associated with healthier
lifestyle, and better health outcomes. Participants completing follow-up had diverse
geographical location, were predominantly female, married, unemployed or retired. At
2.5-year follow-up, nearly 40% were overweight or obese, most were physically active,
non-smokers, consumed little alcohol, used vitamin D/omega-3 supplements, and 42%
reported current disease-modifying drug use. Thirty percentage of reported cane or
gait disability, while 13% relied on major mobility supports (Patient Determined Disease
Steps). Approximately half the respondents reported a comorbidity, 63% screened
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positive for clinically significant fatigue (Fatigue Severity Scale), and 22% screened
positive for depression (Patient Health Questionnaire-9). The validation cohort’s
characteristics were mostly consistent with previously reported HOLISM baseline data.
Conclusions: Exploring prospective associations of modifiable environmental
/behavioral risk factors with health outcomes in this international longitudinal sample of
people with MS will be beneficial to MS research. Impacts of attrition and selection bias
will require consideration. The validation cohort provides opportunity for replication of
previous findings, and also for temporal validation of predictive models derived from the
HOLISM cohort.
Keywords: cohort study, multiple sclerosis, lifestyle, disability, risk factor
BACKGROUND
Multiple sclerosis (MS) is the most common debilitating
neurological disorder affecting young adults (1), impacting
at least 2.3 million people globally in 2013 (2). MS is
characterized by a variety of symptoms including impaired
muscle power, mobility, vision, and symptoms of pain, fatigue,
depression, cognitive dysfunction, loss of bladder control,
and sexual dysfunction. Recently, a wealth of research has
identified behavioral and environmental modifiable lifestyle
factors that may attenuate disease severity, symptoms and/or
comorbidities. The prospective relationships between these
modifiable exposures and outcomes, and the inter-relationships
between variables, however, are yet to be fully elucidated. This
underscores the importance of longitudinal panel studies of
health outcomes and associated factors.
While the etiology of MS progression remains uncertain,
growing evidence suggests an important role for behavioral
and environmental factors including the modifiable lifestyle risk
factors smoking and low vitamin D levels (3, 4). MS progression
may involve inflammatory, metabolic and neurodegenerative
disease processes (5–8) which could be moderated by changes in
lifestyle. Although randomized controlled trials (RCTs) assessing
the impact of lifestyle modification on overall disease course are
lacking (9), there is evidence from observational studies that
healthy lifestyle is associated with fewer comorbidities (10), as
well as less MS symptoms, and slower disability accumulation
and disease progression (11–13), suggesting that secondary
prevention of deterioration may be feasible. The collection
of comprehensive, longitudinal lifestyle, and environmental
exposure data for people with MS is imperative to identify
potential secondary preventive approaches for this population.
We previously explored associations between modifiable
lifestyle risk factors and health outcomes in people with MS in
the baseline cohort of the study, Health Outcomes and Lifestyle
In a Sample of People with Multiple Sclerosis (HOLISM) (14).
In a suite of publications, our baseline findings have suggested
that there are clinically meaningful, cross-sectional associations
between modifiable lifestyle risk factors and health outcomes
in people with MS (11, 15–19). At 2.5 years after the initial
baseline recruitment, we invited participants to complete a
follow-up survey to examine howmodifiable lifestyle risk factors,
clinical disease features, sociodemographic characteristics, and
medication use are prospectively associated with health outcomes
for people with MS
This paper reports in detail the methodology of the 2.5-
year follow-up, and provides an overview of participation,
attrition, and cohort characteristics. Additionally, it documents
the baseline characteristics of a validation sample collected using
the same methodology, contemporaneously to the HOLISM
longitudinal sample 2.5-year wave.
METHODOLOGY
Participants and Data Collection
Adults self-reporting a doctor diagnosis of MS were recruited
for HOLISM baseline between May and August 2012 (14). We
have previously reported only on those participants indicating
a formal diagnosis of MS by a medical doctor; however, people
with a possible MS diagnosis were also permitted to complete the
survey. Participants were recruited over 15 weeks using websites,
mailing lists of MS societies, and web 2.0 platforms such as blogs,
forums, and Facebook pages created specifically for people with
MS, as well as other social media such as Twitter. Participants
provided consent and completed the survey online hosted by
SurveyMonkey.
In November 2014, 2.5 years after the baseline survey, we
invited all participants (including those who indicated a diagnosis
of clinically isolated syndrome or possible MS at baseline) to
complete a follow-up survey. An email inviting participation
contained a link to the survey webpage presenting them with
a participant information sheet, which they were asked to read
before providing consent. Indicating consent was necessary to
continue participation in the survey. The survey was open
between 16 Nov 2014 and 30 Sept 2015, with 75% of the
sample completing the survey within the first month. In order
to capture those participants with contact details that were no
longer current, and to recruit new participants into a validation
cohort (20), we also recruited participants via websites, a mailing
list, and web 2.0 platforms such as blogs, forums, Facebook pages
and groups, and Twitter accounts created specifically for people
with MS. Baseline data were matched to follow-up surveys using
participant IDs, and other identifying information including
name, date of birth and location, and those participants who had
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not participated in the baseline HOLISM survey were identified.
Their data will be analyzed separately as the validation cohort.
The purpose of recruiting this validation cohort was two-fold:
(1) For replicability of our original findings from the HOLISM
cohort; and (2) For temporal validation (21) of predictive
models derived from the HOLISM cohort. Temporal validation,
involves the application of derived and internally validated
models to a sample similar to the derivation sample but recruited
subsequently (20–22).
Ethics approval was granted by St Vincent’s Hospital
MelbourneHumanResearch Ethics Committee (LRR055/12) and
subsequently by The University of Melbourne’s Health Sciences
Human Ethics Sub-Committee (HESC 1545102).
Data Collection Tools
The survey comprised 100 items at baseline and 111 items
at 2.5-year follow-up; however, skip logic enabled participants
to skip items not relevant to them. Survey completion took
approximately 40min, participants were able to take breaks and
even continue the survey on another day if needed.
To allow longitudinal analysis, we predominantly used the
same tools employed at baseline. As described previously (14),
HOLISM surveys included, where possible, questionnaires that
were psychometrically sound and had been tested in comparable
populations. If validated questions or tools were unavailable,
measures were developed by the research team. Further validated
tools not used at baseline were added at the 2.5-year follow-up,
including the Patient Health Questionnaire-9 (23), the Pearlin
Mastery Scale (24), the Performance Scale-Vision Component
(PS-V) (25, 26), the Economic Ladder Question (27), and health
service utilization questions (28). Additional researcher-designed
tools included at 2.5-year follow-up measured sun exposure, oily
fish consumption, and the influence of MS on employment.
The survey consisted of the following domains:
Contact Details
Two email addresses and an email address for a next of kin
were requested. These items were mandatory before being able
to progress to the next part of the survey.
Socio-Demographics
Data were collected for date of birth, sex, current city, and
country of residence (to derive latitude), country of birth, cultural
background, marital status, number of biological, adopted,
and step children, employment status, education level, height,
and weight. Additionally, we included a researcher-derived
categorical question to explore influence of MS on employment,
with nine response options available: “MS has not impacted on
my employment; I have had to cut backmy hours by∼25% due to
MS; I have had to cut back my hours by approximately 50% due
to MS; I have had to cut back my hours by approximately 75%
due to MS; I have had to retire completely due to MS; I have not
progressed in my career due to MS; I have had to quit or change
jobs due to MS; I have had to change my day to day tasks at work
due to MS; I have to take increased sick leave due to MS.” For the
purpose of this paper these categories were collapsed to form a
binary variable: MS impacted on my employment: yes/no.
Cultural background was categorized using the Australian
Standard Classification of Cultural and Ethnic Groups (29), with
an additional free-text “other” response available. Body mass
index (weight/height2) was calculated and classified using the
WHO classification system (30). Data for socioeconomic status
were captured using the Economic Ladder Question: “If you
compare yourself to others in your country, and imagine the
poorest people on the first step and the richest people on the
ninth step, where would you place yourself today?.” While this is
traditionally administered as a pictorial vertical ladder (27), here
it was administered as a horizontal 9-point visual analog scale
with descriptors, “poorest,” “average,” and “richest” from left to
right.
Diagnostic History
Participants’ diagnostic history included confirmation of MS
diagnosis by a medical doctor, year of diagnosis, year of first
symptoms, type of MS upon diagnosis and at time of survey
completion, number of relapses observed by the participant in the
preceding 12 and 60 months, and number of doctor-diagnosed
relapses in the preceding 12 and 60 months. Participants
were provided with a definition of a relapse based on that
given in the North American Research Committee on Multiple
Sclerosis (NARCOMS) survey. Some items for diagnostic history
were modified from the NARCOMS enrolment questionnaire
(obtained from NARCOMS study authors).
Level of Disability
The Patient-Determined Disease Steps (PDDS) was used to
assess level of disability. This is a self-reported analog of the
Expanded Disability Status Scale (EDSS) which is commonly
used by neurologists to assess gait disability (31). The PDDS is
scored ordinally from 0 (normal) to 8 (bed bound) with detailed
descriptors and definitions. For analyses we collapsed these into
three groups: “normal/mild” (scores 0–2 indicating no walking
impairment); “moderate” (scores 3–5 indicating gait disability
or single cane); and “severe” (scores 6–8 indicating requirement
for two canes, a wheelchair or bed).It correlates strongly with
the EDSS and Functional System score (32) and is considered a
practical tool to assess changes in disability over time (33). The
patient-derived Multiple Sclerosis Severity Score (P-MSSS) (34)
was used as an additional indicator of disease status. Essentially
analogous to the MSSS (35), it estimates the disease duration-
adjusted level of disability as measured by PDDS, such that the
same PDDS after a shorter disease duration will realize a higher
P-MSSS than the same PDDS later in disease. Higher scores
on the P-MSSS denote greater disease severity. In calculating
the P-MSSS we referred to the previously published Disability
Expectancy Table (34).
Comorbidities
The Self-Administered Comorbidity Questionnaire (SCQ) is
a self-report tool to assess the presence of comorbidities in
the absence of medical record review (36). The SCQ has
demonstrated criterion validity when assessed against medical
records (37), and has been used in studies of participants with
MS (38, 39). We modified this tool, retaining the item regarding
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whether the comorbidity is currently present and omitting items
relating to whether treatment is received and if the condition
limits activities. For this study, rheumatoid and osteoarthritis
conditions were combined into one, and due to anticipated high
prevalence, anxiety was also included as a condition.
Vision
We assessed participant level of visual impairment using the
vision component of the validated Performance Scale (PS-V)
(25, 26), used in NARCOMS. Participants were asked to describe
their overall visual condition (with glasses if used) over the
preceding month, and to compare this current condition to the
vision they had before developing MS. The PS-V uses a 6-point
scale (“normal vision” to “total visual disability”) with detailed
descriptors. It is strongly correlated with the Impact of Visual
Impairment Scale, which assesses vision-related quality of life
(QoL) by self-report (r = 0.66, p= 0.0001) (40).
Health-Related Quality of Life
The Multiple Sclerosis Quality of Life-54 (MSQOL-54) was
used to measure health-related QoL (41). This tool was
developed from the RAND 36-item health survey (SF-36) and is
supplemented with 18 additional items. The MSQOL-54 consists
of 54 items from which 12 sub-scales and two single items
are calculated, which together yield two composite scores: the
physical health composite (PHC) and mental health composite
(MHC).
Fatigue
The 9-item Fatigue Severity Scale (FSS) (42) was used to assess
clinically significant fatigue. A mean score ≥4 has been used as a
cut-off to indicate clinically significant fatigue and is widely used
for people with MS (43–45). It has good internal consistency,
stability, and sensitivity to change over time (45, 46).
Depression
To assess depression risk at 2.5-year follow-up, we used the
Patient Health Questionnaire (PHQ-9), a widely used depression
risk screening tool validated in people with MS (23, 47). The
PHQ-9 has comparable psychometric properties to the CESD-
10, and PROMIS-D-8 when tested in people with MS (48).
The short version of this tool, the PHQ-2 was used at baseline
and comprises two-items of the PHQ-9. We opted for the
longer version at follow-up in view of its superior psychometric
characteristics.We report those at risk for depression with cut-off
at≥10 on the PHQ-9 (49). For the PHQ-2 (baseline and 2.5-year
follow-up) we applied a cut-off of ≥3 (50).
Medication Use
A list of 25 disease-modifying drugs (DMDs) and other common
MS medications including generic and trade names were
provided. Medications for which data were collected were the
same as described at baseline with the addition of Peginterferon
beta-1a (PLEGRIDY R©). Participants were asked to indicate
current and previous use, and the length of time taken.
Participants were also asked to indicate whether they
took prescription, over-the-counter, or herbal remedies for
10 symptomatic conditions: depression, anxiety, headaches,
pain other than headaches, fatigue, difficulty sleeping, bladder
problems, bowel problems, spasticity, and “other.”
Health Service Use
Participants were asked four questions relating to the frequency
of health service use over the preceding 6 months based on items
in the Stanford Chronic Disease Self-Management Study (28), the
validity of which has been demonstrated (51). Data were collected
for visits to a medical doctor, visits to emergency rooms, number
of overnight stays in hospital, and total nights spent in hospital.
Dietary Habits
To minimize respondent burden, we selected a brief dietary
screening tool rather than a food diary or Food Frequency
Questionnaire. Since we aimed to assess diet broadly with a
particular consideration for fats, we modified the Diet Habits
Questionnaire (DHQ) (52). The DHQwas developed in line with
nutrition recommendations by the National Heart Foundation
of Australia, and the Dietary Guidelines for Australian Adults
developed by the National Health & Medical Research Council
and the Commonwealth Department of Health and Aging. The
original 24-item DHQ has eight dietary sub-scores, and assesses
intake of saturated and unsaturated fat, fruit and vegetables,
fiber, takeaway foods, snack habits, and omega-3 consumption,
among other estimates. For the purpose of the HOLISM study
we removed three items regarding sodium intake, and one
item on alcohol (53). For questions relating to oils and fats,
participants were provided with examples of vegetable oil,
mono-unsaturated oil, and polyunsaturated oil to which they
could refer. Concurrent validity for the original DHQ has been
established for an Australian cardiac disease population (52).
For the 2.5-year timepoint, we added a researcher-devised
item regarding oily fish consumption that was separate from the
DHQ: “How often do you eat oily fish such as sardines, mackerel,
herring, salmon, tuna or trout?,” with available responses
including Never; Less than once a week; About 1–2 times a week;
About 3–4 times a week; At least 5 times a week.
Alcohol Consumption
Frequency of alcohol consumption was assessed on an 11-point
ordinal scale (never drink to drink daily), collapsed to a five-
point scale (non-drinker, rarely, <1/week, 1–3 days a week, 4
days/week to daily). Data for volume normally consumed were
collected on an 11-point scale (ranging from “not applicable” to
10+ standard drinks per day) with examples provided for what
constituted a “standard drink.” Based on prior classifications
(54), “low” consumption was defined as<15 g/week; “moderate”
consumption was defined as 15–210 g/week (or up to 30 g/day)
for women and 15–315 g/week (or up to 45 g/day) formen; “high”
consumption was considered>210 g/week (30 g/day) for women
or>315 g/week (>45 g/day) for men.
Smoking
Current smoking status was queried as current/former/never,
while number of tobacco products smoked was assessed using six
categories (<1 per day, 1–5 per day, 6–10 per day, 11–15 per day,
16–20 per day, to>20 per day). Duration of smoking (years) was
collected on an interval scale. Time since quitting if previously
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smoked was queried as <6-months; 6-<12-months; 1-<2-years;
2-<3-years; 3-<4-years; 4-<5-years; 5-<10-years; more than 10
years ago, subsequently collapsed into three categories (<12-
months; 12-months-10-years; 10-years+).
Sunlight Exposure
Questions relating to sun exposure were modified from the
Ausimmune Longitudinal Study in people withMS (55). For each
of summer and winter, participants were asked to report number
of days per week they were out in the sun; the average duration
spent in the sun on days they were out in the sun (none, 1–
15min, 16–30min, 31-60min,>60min); frequency of sunscreen
applied to the majority of exposed skin (never, sometimes, often,
always); frequency of wearing clothes that covered most of the
body (never, sometimes, often, always); frequency of wearing
clothes that exposed much of the body (never, sometimes, often,
always).
A researcher-devised item explored participants’ 12-month
average weekly frequency of “adequate” sun exposure. We
defined adequate sun exposure as “10–15min of sunlight on days
with UV index of 7” (more or less time if the UV index was
lower or higher). Response options were never, less than once
a week, 1–2 times per week, 3–4 times per week, 5–6 times per
week, every day, unsure. Also, participants were asked: the color
of their untanned skin (very light; light; intermediate; tanned;
brown; dark) based on existing classification (56).
Vitamin D
Participants were asked whether they intentionally exposed
themselves to the sun to raise their vitamin D level; whether they
took a vitamin D supplement and, if so, the dosage and frequency
of their vitamin D supplementation, and the duration of vitamin
D supplementation (<6 months; 6 to <12 months; 1 year to <2
years; 2 to <3 years; 3 to <4 years; 4 to <5 years; 5 to <10 years;
≥10 years).
Omega-3 Fatty Acids
Items included both the type and daily dosage of omega-3
supplementation used on average in the last 12 months. Types
of omega-3 included fish oil, high-potency fish oil, flaxseed oil,
and “other” free-text responses.
Physical Activity
We used the International Physical Activity Questionnaire-
Short Form (IPAQ-SF), a 7-day recall of the frequency and
duration of vigorous and moderate physical activity, walking,
and sitting assessed in nine items (57). Items can be scored
separately, as a combined total score, or the number of metabolic
equivalent of task (MET) minutes can be calculated. Using
established scoring instructions, we categorized data into low
activity level (no activity reported or insufficient to be other
levels), moderate activity level (3+ days of vigorous at least 20
min/day, 5+ days of moderate/walking at least 30 min/day, or
any combination of 600+ MET-min/week); and high activity
level (at least 1,500 vigorous MET-min/week, at least 3,000
total MET-min/week).The IPAQ and its short form have been
validated in several studies and populations globally, and both
the long form (58, 59) and the short form (60, 61) have been
used previously for people withMS. The short form has also been
validated with accelerometers (62).
Meditation
Two researcher-devised items measured the 12-month average
weekly frequency and duration of meditation: “On average in
the last 12 months how often have you meditated” (never; less
than once per week; 1–2 times per week; 3–4 times per week; 5–
6 times per week; everyday); and “On average, how long do you
meditate for (in minutes) each time?.” For the latter, the response
format measured duration in 5-min increments up to “more than
60min.”
Social Support
The relationship between social support and health has long
been acknowledged (63). We used the Single Item Measure of
Social Support (SIMSS) to determine the number of people that
provided support to participants (64): “Howmany people do you
have near you that you can readily count on for help in times
of difficulty, such as watch over children or pets, give rides to
hospital or store, or help when you are sick?” (0, 1, 2–5, 6–9, 10,
or more).
Engagement With OMS
Three items queried participants’ engagement in resources
(books, website, and educational workshops) provided by
the not-for-profit charitable organization Overcoming Multiple
Sclerosis (OMS), for which several of the researchers had
previously facilitated lifestyle educational sessions for people with
MS. OMS promotes a healthy lifestyle (no smoking, regular
vigorous exercise, daily meditation, plant-based whole food diet
low in saturated fat, plus seafood and omega-3 supplementation,
regular sun exposure and vitamin D supplementation) with the
aim of reducing relapses, MS symptoms, and disability accrual.
The HOLISM study was conceived by the founder of OMS, and
the HOLISM study and OMS are funded by the same charity.
Mastery
The Pearlin Mastery Scale (Mastery-S) (24), a 7-item scale, was
used to assess the extent to which individuals felt they manifested
personal mastery over important life outcomes. Participants
were presented with statements regarding their ability to control
and master aspects of life and provided four response options:
strongly disagree, disagree, agree, or strongly agree. Items were
summed to a total score ranging from 7 to 28. The Mastery-S
has demonstrated internal reliability both in general populations
(0.72) (24) and adults with MS (0.75) (65).
Data Analysis
For both cohorts, we reported descriptive statistics: number
(percentage) for categorical variables; mean (standard deviation)
for continuous variables; and median (25–75th percentile) for
skewed variables. The baseline characteristics of the participants
who completed or dropped-out at 2.5-year follow-up were also
reported, and univariable logistic regression was used to explore
whether these characteristics are associated with the missingness
at the 2.5-year follow-up. All statistical analyses were completed
using Stata/SE, version 15.0 (StataCorp, College Park, Texas).
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RESULTS
HOLISM Longitudinal Cohort, Participation
at 2.5-Year Follow-Up
Of 2,990 that consented to participate at baseline, 524 were
excluded leaving 2,466 people with MS at baseline (Figure 1).
Of these baseline participants with diagnosed MS, 1,401 (56.8%)
provided data at the 2.5-year wave. A further 30 participants
that commenced the initial baseline survey but did not report a
diagnosis of MS at baseline (and were therefore not included in
previous reports of our baseline sample), indicated a subsequent
diagnosis of MS at 2.5-year follow-up. Since they did not have
definite MS at baseline, these 30 participants were not included
in longitudinal analyses.
HOLISM Longitudinal Cohort, Attrition at
2.5-Year Follow-Up
In total, 1,063 baseline participants did not complete 2.5-year
follow-up, 43.2% of the baseline sample with diagnosed MS.
Survey completion at 2.5 years was greater for participants
who had reported higher educational attainment (Table 1),
better health outcomes (Table 2), engagement in OMS resources
(Table 3), and healthier lifestyle (Table 4) at baseline.
HOLISM Longitudinal Cohort,
Characteristics at 2.5-Year Follow-Up
Participants in the HOLISM longitudinal cohort (completing
baseline and 2.5-year follow-up) were predominantly female,
residing in Australasia, Europe or North America, married, and
either employed or retired due to medical reasons or disability
(Table 1). Participants were highly educated, with approximately
two thirds having completed a tertiary level study. Most had
relapsing-remitting MS (RRMS) (Table 3), and 29% reported use
of a cane or disability affecting gait (Table 2). Those retained in
the study fluctuated in disability across the 2.5 year follow-up
period [normal/mild−4 (−0.3%);moderate−42 (−3.0%); severe
+60 (+4.2%); missing−14 (−1.03%)].
FIGURE 1 | Flowchart of participation.
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TABLE 1 | Sociodemographic characteristics of the 2.5-year and validation cohorts and the baseline characteristics of the participants who completed and were lost to
follow-up at 2.5-year follow-up.
Baseline, completed 2.5-year
(Number (%) unless stated
otherwise) (n = 1,401)
Baseline, not completed
2.5-year (Number (%) unless
stated otherwise) (n = 1,065)
2.5-year (Number (%)
unless stated otherwise)
(n = 1,401)
Validation (Number (%)
unless stated otherwise)
(n = 573)
SOCIODEMOGRAPHICS
Sex
Male 241 (17.3) 174 (18.1) 241 (17.3) 102 (19.2)
Female 1,150 (82.7) 787 (81.9) 1,150 (82.7) 430 (80.8)
(Missing) (10 (0.7)) (104 (9.8) ∧) (10 (0.7)) (41 (7.2))
REGION OF RESIDENCE
Australasia 560 (40.1) 275 (25.9) 564 (40.3) 199 (34.7)
Europe 380 (27.2) 279 (25.2) ∧ 378 (27.0) 234 (40.8)
North America 426 (30.5) 487 (45.8) ∧ 430 (30.7) 128 (22.3)
Other 30 (2.2) 33 (3.1) ∧ 29 (2.1) 8 (1.40)
(Missing) (5 (0.4)) (2 (0.2)) (0 (0)) (4 (0.70))
MARITAL STATUS
Married 856 (61.8) 615 (59.0) 857 (62.3) 345 (60.2)
Cohabiting/partnered 195 (14.1) 121 (11.6) 190 (13.8) 88 (15.4)
Separated/divorced/widowed 147 (10.6) 136 (13.1) 168 (12.2) 60 (10.5)
Single 187 (13.5) 170 (16.3) 160 (11.6) 75 (13.1)
(Missing) (16 (1.1)) (23 (2.2)) (26 (1.9)) (5 (0.9))
NUMBER OF CHILDREN
None 473 (33.8) 342 (32.1) 442 (31.6) 222 (38.4)
One or more 904 (64.5) 694 (65.2) 923 (65.9) 341 (59.5)
(Missing) (24 (1.7)) (29 (2.7)) (36 (2.6)) (10 (1.8))
NUMBER OF SUPPORT PEOPLE
None 51 (3.6) 66 (6.2) 43 (3.1) 23 (4.0)
One 267 (19.1) 210 (19.7) 271 (19.3) 101 (17.6)
Two to five 810 (57.8) 518 (48.6) 795 (56.8) 316 (55.2)
Six or more 194 (13.9) 107 (10.1) 156 (11.1) 63 (11.0)
(Missing) (79 (5.6)) (164 (15.4) ∧) (136 (9.7)) (70 (12.2))
EMPLOYMENT
Unemployed, not seeking
employment
61 (4.4) 63 (6.0) 60 (4.4) 29 (5.1)
Retired due to age 55 (3.9) 18 (1.7) 79 (5.7) 19 (3.3)
Retired for medical/disability
reasons
277 (19.8) 297 (28.1) ∧ 336 (24.4) 107 (18.7)
Other 13 (0.9) 9 (0.9) 17 (1.2) 7 (1.2)
(Missing) (3 (0.2)) (7 (0.7)) (23 (1.6)) (1 (0.2))
LEVEL OF EDUCATION COMPLETED
No formal
schooling/primary/secondary
only
292 (21.0) 311 (29.3) 268 (19.4) 135 (23.6)
Vocational school 203 (14.6) 193 (18.2) 212 (15.4) 90 (15.7)
Bachelor’s degree 533 (38.3) 354 (33.4) 516 (37.4) 207 (36.1)
Post-graduate study 364 (26.2) 202 (19.1 385 (27.9) 139 (24.3)
(Missing) (9 (0.6)) (5 (0.5)) (20 (1.4)) (2 (0.4))
Age* 45.9 (10.5) 45.3 (10.5) 48.4(10.5) 46.2 (11.0)
(Missing, n (%)) (0 (0.0)) (38 (3.6)) (0 (0.0)) (0 (0.0))
Latitude* 41.0 (8.8) 41.0(8.6) 41.0 (8.8) 42.6 (8.9)
(Missing, n (%)) (3 (0.2)) (2 (0.2)) (0 (0.0)) (0 (0.0))
Comparative socioeconomic
status**
- - 5 (5-6) 6 (5–6)
*Mean (standard deviation).
**Median (25–75th percentile).
The baseline characteristics that are associated with missingness at 2.5 year follow-up are highlighted in gray with ∧ indicating the variables that are associated with higher odds of
missingness at 2.5 year follow-up. For categorical variables, the reference category was taken as the first presented category in the table, and an arbitrary p-value cut-off of 0.05 was
used.
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TABLE 2 | Anthropometric and clinical characteristics of the 2.5-year and validation cohorts and the baseline characteristics of the participants who completed and were
lost to follow-up at 2.5-year follow-up.
Baseline, completed 2.5-year
(Number (%) unless stated
otherwise) (n = 1,401)
Baseline, not completed
2.5-year (Number (%) unless
stated otherwise) (n = 1,065)
2.5-year (Number (%)
unless stated otherwise)
(n = 1,401)
Validation (Number (%)
unless stated otherwise)
(n = 573)
ANTHROPOMETRIC AND CLINICAL
Body Mass Index
Underweight (<18.5) 71 (5.1) 35 (3.4) 60 (4.3) 31 (5.4)
Normal (18.5–<25) 792 (56.6) 501 (48.1) 781 (55.8) 299 (52.2)
Overweight (25 – <30) 304 (21.7) 252 (24.2) 304 (21.7) 126 (22.0)
Obese (≥30) 232 (16.6) 253 (24.3) ∧ 254 (18.2) 107 (18.7)
(Missing) (2 (0.1)) (24 (2.3) ∧ ) (2 (0.1)) (10 (1.75))
NUMBER OF COMORBIDITIES
0 516 (36.8) 340 (31.9) 715 (51.0) 321 (56.0)
1 392 (28.0) 232 (21.8) 366 (26.1) 131 (22.9)
2 270 (19.3) 216 (20.3) 182 (13.0) 61 (10.7)
≥3 223 (15.9) 277 (26.0) ∧ 138 (9.9) 60 (10.5)
CURRENTLY USE A DISEASE MODIFYING DRUG?
No 747 (53.3) 574 (53.9) 812 (58.0) 310 (54.1)
Yes 654 (46.7) 491 (46.10) 589 (42.0) 263 (45.9)
DISABILITY LEVEL (PATIENT-DETERMINED DISEASE STEPS)
Normal/mild 787 (56.2) 476 (44.7) 783 (55.9) 343 (59.9)
Moderate 442 (31.6) 353 (33.2) ∧ 400 (28.6) 169 (29.5)
Severe 117 (8.4) 123 (11.6) ∧ 177 (12.6) 48 (8.4)
(Missing) (55 (3.93)) (113 (10.6) ∧) (41 (2.9)) (13 (2.3))
Mental Health Composite
Quality Of Life (MSQOL-54) *
70.3 (19.6) 61.6 (22.7) 70.3 (20.4) 68.9 (20.6)
(Missing, n (%)) (74 (5.3)) (122 (11.5) ∧) 85 (6.07) (46 (8.0))
Physical Health Composite
Quality Of Life (MSQOL-54) *
63.4 (32.3) 54.6 (33.8) 60.9 (30.4) 65.1 (32.8)
(Missing, n (%)) (42 (3.0)) (68 (6.4) ∧) 43 (3.07) (12 (2.1))
DEPRESSION RISK (PATIENT HEALTH QUESTIONNAIRE−9 SCORE)
0 – 4: no depression - - 607 (48.0) 245 (42.8)
5–9: minimal depression
symptoms
383 (30.3) 134 (23.4)
10–14: likely major
depression, mild
144 (11.4) 81 (14.1)
15–19: likely major
depression, moderate
93 (7.4) 26 (4.5)
≥20: likely major depression,
severe
37 (2.9) 21 (3.7)
(Missing) (137 (9.8)) (66 (11.5))
DEPRESSION RISK (PATIENT HEALTH QUESTIONNAIRE−2 SCORE)
0–2: negative 1139 (81.3) 660 (62.0) 1119 (79.9) 441 (77.0)
≥3: positive 181 (12.9) 244 (23.0) ∧ 190 (13.6) 82 (14.3)
(Missing) (81(5.8)) (161 (15.1) ∧) (92(6.6)) (50 (8.7))
FATIGUE, AS DEFINED BY FATIGUE SEVERITY SCALE >35
No fatigue 484 (34.6) 251 (23.6) 476 (37.5) 201 (35.1)
Fatigue 784 (56.0) 619 (58.1) 792 (62.5) 308 (53.8)
(Missing) (133 (9.5)) (195 (18.3)) (133 (9.5)) (64 (11.2))
Pearlin Mastery Scale** - - 21 (19-25) 21 (18-24)
(Missing) (146 (10.4)) (71 (12.4))
(Continued)
Frontiers in Neurology | www.frontiersin.org 8 December 2018 | Volume 9 | Article 1074
Weiland et al. HOLISM Longitudinal and Validation Cohorts
TABLE 2 | Continued
Baseline, completed 2.5-year
(Number (%) unless stated
otherwise) (n = 1,401)
Baseline, not completed
2.5-year (Number (%) unless
stated otherwise) (n = 1,065)
2.5-year (Number (%)
unless stated otherwise)
(n = 1,401)
Validation (Number (%)
unless stated otherwise)
(n = 573)
PERFORMANCE SCALE—VISION COMPONENT (PS-V)
Normal 603 (43.0) 225 (39.3)
Minimal 430 (30.7) 156 (27.2)
Mild 201 (14.4) 95 (16.6)
Moderate 57 (4.1) 23 (4.0)
Severe 11 (0.8) 10 (1.8)
Total 1 (0.1) 1 (0.2)
(Missing) (98 (7.0)) (63 (11.0))
*Mean (standard deviation).
**Median (25–75th percentile).
The baseline characteristics that are associated with missingness at 2.5-year follow-up are highlighted in gray with ∧ indicating the variables that are associated with higher odds of
missingness at 2.5-year follow-up. For categorical variables, the reference category was taken as the first presented category in the table, and an arbitrary p-value cut-off of 0.05 was
used.
Approximately 40% were overweight or obese, and most
were physically active to a moderate or high level. Most
participants were ex-smokers or never smokers, consumed low
amounts of alcohol, and used vitamin D and/or omega-3 fatty
acid supplementation. At the time of survey completion, 42%
reported currently taking a disease-modifying drug (Table 4).
Half of the respondents of the 2.5-year wave reported having
a comorbidity, and the rate of clinically significant fatigue was
high (62.5%). One-fifth screened positive for depression (PHQ-9
at cut off≥10), and 50% reported some level of visual impairment
(Table 2).
Validation Cohort Participation and
Characteristics
We recruited 573 participants into the HOLISM validation
cohort. Overall, this cohort was similar to the original HOLISM
baseline cohort (14) but small differences were seen in
number of children (Table 1), MS type (Table 3), vitamin D
supplementation, and use of meditation for stress reduction
(Table 4).
DISCUSSION
The importance of lifestyle has only relatively recently been
identified by key stakeholders as a critical area for further
research (66, 67). A comprehensive body of literature exists
that suggests modifiable risk factors, such as lifestyle, play a
pivotal role in MS disease progression and associated morbidity
(4, 12, 68–72). Yet there remain critical gaps in the literature with
respect to modification of these factors. Multiple large national
and international MS registries exist that collect longitudinal data
(73), several of which have also begun to collect data regarding
lifestyle and/or environment. However, our HOLISM study is the
first to examine a broad range of lifestyle factors together with
disease characteristics, medication use, and health outcomes in a
worldwide sample.
Longitudinal research designs are arguably of great
importance in the initial identification of exposure-outcome
associations within populations. The longitudinal design offers
advantages, including the capacity to separate change over time
within participants (i.e., effects of time or age) from differences
between participants at baseline (i.e., cohort effects), as well as
the determination of temporal relationships permitting inference
regarding prospective interpretations (74). Findings from
epidemiological studies such as ours may instigate longitudinal
RCTs, the gold standard in establishing causation. We previously
reported baseline findings from the HOLISM study which
revealed a broad exposure gradient in terms of lifestyle behavior
adopted by this international sample, rendering the sample a
powerful tool to identify such associations. The current paper
reports on follow-up data for the HOLISM sample collected at
the 2.5-year wave, and data from a validation sample.
HOLISM Longitudinal Cohort
Participation and Attrition
Despite our attempts to minimize survey dropout by sending
multiple email reminders to participants and advertising the
follow-up wave through websites and social media used to recruit
the baseline survey, our attrition rate was high. Of the 2,466 with
confirmed MS that provided baseline data, 1,401 completed the
survey at 2.5-year follow-up, an overall response rate of 56.8%
for those included in baseline analyses. While there are many
possible reasons for attrition, it is likely that the web-based nature
of recruitment, the geographically diverse nature of the cohort
and limited contact information all contributed to attrition; a
single email address was collected from participants at baseline.
Participant attrition, an inherent characteristic of almost every
longitudinal study, represents a considerable threat to validity;
retaining a large, representative portion of the original sample
is critical both for statistical power and generalizability (75)
and to minimize the potential for selection bias in analyses of
associations between exposures and outcomes if participants who
are retained in the study are systematically different to those who
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TABLE 3 | MS-Specific characteristics of the 2.5-year and validation cohorts and the baseline characteristics of the participants who completed and were lost to
follow-up at 2.5-year follow-up.
Baseline, completed 2.5-year
(Number (%) unless stated
otherwise) (n = 1,401)
Baseline, not completed
2.5-year (Number (%) unless
stated otherwise) (n = 1,065)
2.5-year (Number (%)
unless stated otherwise)
(n = 1,401)
Validation (Number (%)
unless stated otherwise)
(n = 573)
MS-SPECIFIC
Type Of Ms At Completion Of Survey
Benign 64 (4.6) 36 (3.5) 85 (6.2) 19 (3.3)
RRMS 875 (63.3) 616 (59.4) 810 (59.2) 386 (67.4)
SPMS 144 (10.4) 131 (12.6) 199 (14.6) 59 (10.3)
PPMS 100 (7.2) 75 (7.2) 111 (8.1) 40 (7.0)
PRMS 18 (1.3) 30 (2.9) 23 (1.7) 5 (0.9)
Unsure/other 181 (13.1) 149 (14.4) 140 (10.2) 53 (9.3)
(Missing) (19 (1.4)) (28 (2.6)) (33 (2.4)) (11 (1.9))
Patient-derived Multiple
Sclerosis Severity Score**
4.4 (2.4–7.3) 5.5 (2.9-7.6) ∧ 4.9 (2.6 – 7.3) 4.5 (3.0-7.7)
(Missing, n (%)) (66 (4.7)) (132 (12.4) ∧ ) (49 (3.5)) (25 (4.4))
Disease duration since
diagnosis, years**
5.4 (2.4–11.4) 6.4 (2.6–12.4) ∧ 7.9 (5.0–13.9) 4.8 (2.1–12.2)
(Missing, n (%)) (0 (0.0)) (29 (2.7) ∧ ) (0 (0.0)) (8 (1.4))
Disease duration since
symptom onset, years**
11.4 (5.4–20.2) 12.4 (6.6−20.6) ∧ 14.2 (8.1–23.2) 11.2 (5.2,20.2)
(Missing, n (%)) (2 (0.1)) (37 (3.5) ∧ ) (3 (0.2)) (10 (1.7))
Number of
doctor-diagnosed relapses
in previous 12 months in
relapsing-remitting MS **
0 (0–1) 0 (0–1) 0 (0–1) 0 (0-1)
(Missing, n (%)) (28 (3.2)) (17 (2.8)) (18 (2.2)) (2 (0.5))
CURRENTLY EXPERIENCING SYMPTOMS DUE TO A RECENT RELAPSE IN RELAPSING-REMITTING MS
No 535 (61.1) 360 (58.4) 576 (71.1) 229 (59.3)
Yes 225 (25.7) 190 (30.8) 147 (18.2) 112 (29.0)
Unsure 114 (13.0) 64 (10.4) 80 (9.9) 43 (11.1)
(Missing) (1 (0.1)) (2 (0.3)) (7 (0.9)) (2 (0.5))
OVERCOMING MULTIPLE SCLEROSIS (OMS) ENGAGEMENT
No OMS resources 350 (25.0) 445 (41.8) 335 (23.9) 149 (26.0)
Website only 257 (18.3) 239 (22.4) 193 (13.8) 101 (17.6)
Book only 43 (3.1) 30 (2.8) 55 (3.93) 10 (1.8)
Retreat only 1 (0.1) 1 (0.1) 2 (0.1) 2 (0.4)
Book and website only 576 (41.1) 278 (26.1) 591 (42.2) 219 (38.2)
Website and retreat only 2 (0.1) 3 (0.3) 1 (0.1) 4 (0.7)
Book and retreat only 5 (0.4) 8 (0.8) 7 (0.5) 0 (0)
Book, retreat and website 167 (11.9) 61 (5.7) 217 (15.5) 88 (15.4)
HEALTH SERVICE UTILIZATION, PAST 6 MONTHS
Number of visits to a
medical doctor**
2 (1-3) 2 (1-4)
VISITS TO EMERGENCY DEPARTMENT
No 1,140 (81.4) 424 (74)
Yes 154 (11) 102 (17.8)
(Missing) (107 (7.6)) (47 (8.2))
OVERNIGHT STAYS IN HOSPITAL
Yes 87 (6.2) 52 (9.1)
Number of nights 0(0-0) 0 (0-0)
No 1,196 (85.344) 468 (81.7)
(Missing) (118 (8.4)) (53 (9.3))
(Continued)
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TABLE 3 | Continued
Baseline, completed 2.5-year
(Number (%) unless stated
otherwise) (n = 1,401)
Baseline, not completed
2.5-year (Number (%) unless
stated otherwise) (n = 1,065)
2.5-year (Number (%)
unless stated otherwise)
(n = 1,401)
Validation (Number (%)
unless stated otherwise)
(n = 573)
MS IMPACTED MY EMPLOYMENT
No 516 (36.8) 230 (40.1)
Yes 842 (60.1) 330 (57.6)
(Missing) (43 (3.1)) (13 (2.3))
*Mean (standard deviation).
**Median (25-75th percentile).
# =The baseline characteristics that are associated with missingness at 2.5 year follow-up are highlighted in gray with ∧ indicating the variables that are associated with higher odds of
missingness at 2.5 year follow-up. For categorical variables, the reference category was taken as the first presented category in the table, and an arbitrary p-value cut-off of 0.05 was
used.
are lost to follow up. We explored the baseline characteristics
of those who participated in the 2.5-year follow-up compared
to those who did not. In general, our retained sample was
healthier, more educated, and more often employed than those
not retained. This notable participation bias is a commonly
encountered limitation in most longitudinal studies, which can,
in some instances, be managed or minimized using modern
missing data methods in multivariable models (76). The impact
of these biases on results will be addressed in consequent papers
using these data.
Specifically, compared to those missing at 2.5-years, those
that completed 2.5-year follow-up reported substantially greater
baseline frequencies of residing in Australasia, screening negative
for depression risk, and higher mental and physical health
quality of life. Among completers, there were substantially higher
baseline frequencies of taking an omega-3 and/or vitamin D
supplement, and being engaged in OMS resources. Compared
with completers, those lost to follow-up were more likely to have
indicated that they were more disabled, retired due to medical
reasons or disability, obese, have less healthy dietary habits,
higher consumption of alcohol, three or more comorbidities,
higher MS severity, and longer disease duration. Together these
data suggest that non-completion in our HOLISM longitudinal
cohort may be associated with poorer health status, poorer
lifestyle, greater disease severity and longer duration of the
disease.
While we used strategies to minimize survey dropout, it is
notable that a greater number of participants in Australasia
indicated engagement with the OMS website at baseline; this may
have increased bias toward healthy lifestyle in this second wave.
This suggests that people who participated in the follow up study
are unlikely to be representative of the baseline HOLISM survey.
Characteristics of 2.5-Year Sample
At the 2.5-year wave of the HOLISM longitudinal study we
retained a geographically diverse range of English speaking
participants based predominantly in Australasia, Europe, or
North America. We retained a high proportion of females at the
2.5-year follow-up (4.8:1 female:male ratio), which is an over-
representation from the estimated incidence sex ratio for people
living with MS (female:male) of 2.3–3.5:1 (77), and differs from
samples thought to be representative (78). This is unsurprising
since previous studies have demonstrated higher participation
rates by women in web-based studies (79) and survey research
generally. Our sample reported a median of 7.9 years duration
since diagnosis. While secondary progressive MS takes many
years to develop (80), our cohort is approaching a time at which
some may begin to experience changes in MS specific symptoms,
comorbidities, and disability (81), offering us the opportunity
to explore associations between these health outcomes and
exposures.
Our cohort is highly educated, with the majority reporting
having completed a bachelor or higher degree. This is relevant
since there is known to be a strong association for education with
health behavior, health status, and health literacy including the
application of information about prevention and treatment (82).
Among people with MS, higher education levels are associated
with better health care engagement (83), cognitive reserve (84),
superior health related QoL (85), and lower levels of disability
(86), although these latter two findings were not confirmed
in one large registry study (87). A substantial proportion of
our population were retired due to disability or illness, and
most participants indicated that MS had impacted on their
employment. These are important surrogates for the significant
burden of disease of MS.
Consistent with what may be expected from prevalence
statistics, themajority (n= 810, 59%) of our participants reported
having RRMS. Notably, only 42% (589) of participants in our
sample reported current DMD use. Possible underlying reasons
for this require further exploration. It is conceivable that our
observation is influenced by the fact that many participants came
from countries where DMDs are not reimbursed by healthcare
systems. Regardless, these findings are concerning given that
delayed initiation of DMD treatment is associated with a more
rapid disease progression and mortality (88). Interestingly, 140
participants were unsure of their MS type, despite, re-confirming
MS diagnosis on study entry; this number is not dissimilar to
that reporting a relapse at the time of the survey completion (n
= 147). It is possible that at least a subset of participants unsure
of their disease status were awaiting either symptom remission
or neurology review to determine classification. However, we
cannot exclude the possibility that some did not have MS.
Lifestyle and health behavior of the cohort were typically
favorable. In contrast to other studies (89), very few smokers
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TABLE 4 | Lifestyle characteristics of the 2.5-year and validation cohorts and the baseline characteristics of the participants who completed and were lost to follow-up at
2.5-year follow-up.
Baseline, completed 2.5-year
(Number (%) unless stated
otherwise) (n = 1,401)
Baseline, not completed
2.5-year (Number (%) unless
stated otherwise) (n = 1,065)
2.5-year (Number (%)
unless stated otherwise)
(n = 1,401)
Validation (Number (%)
unless stated otherwise)
(n = 573)
LIFESTYLE
Smoking Status
Never 707 (50.5) 392 (36.8) 701 (50.0) 275 (48.0)
Ex-smoker 520 (37.1) 388 (36.4) 527 (37.6) 216 (37.7)
Current smoker 114 (8.1) 167 (15.7) 102 (7.3) 43 (7.5)
(Missing) (60 (4.3)) (118 (11.1)) (71 (5.1)) ((39 (6.8))
ALCOHOL INTAKE
No alcohol intake 516 (36.8) 478 (44.9) 461 (32.9) 184 (32.1)
Limited (1 std/d female, 2
std/d male)
631 (45.0) 339 (31.8) 637 (45.5) 256 (44.7)
Heavy (>1 std/d female, >2
std/d male)
180 (12.9) 106 (9.9) 157 (11.2) 78 (13.6)
(Missing) (74 (5.3)) (142 (13.3) ∧) (146 (10.4)) (55 (9.6))
PHYSICAL ACTIVITY (INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE)
Low 419 (29.9) 328 (30.8) 396 (28.3) 126 (22.0)
Moderate 540 (38.5) 310 (29.1) 563 (40.2) 222 (38.7)
High 316 (22.6) 217 (20.4) 314 (22.4) 156 (27.2)
(Missing) (126 (9.0)) (210 (19.7) ∧) (128 (9.1)) (69 (12.0))
ADEQUATE SUN EXPOSURE IN PRECEDING 12 MONTHS
Never/<once per week 392 (31.8) 263 (31.1) 298 (25.4) 124 (22.3)
1–2 times per week 368 (29.9) 223 (26.4) 320 (27.2) 115 (22.1)
3–4 times per week 258 (20.9) 182 (21.5) 306 (26.0) 126 (22.0)
5–6 times per week 133 (10.8) 86 (10.2) 169 (14.4) 65 (11.3)
Every day 81 (6.6) 92 (10.9) 82 (7.0) 39 (6.8)
(Missing) (169 (12.1)) (219 (20.6)) (226 (16.1)) (100 (17.4))
Diet Habits Questionnaire
total score**
82 (73–91) 77 (67–85) 80 (70–89) 84.5 (72 92)
(Missing) (55 (3.9)) (118 (11.8)∧) (69 (4.9)) (37 (6.4))
VITAMIN D
None 279 (19.9) 343 (32.2) 278 (19.8) 112 (19.6)
<2000 International Unit
(IU)/day
188 (13.4) 114 (10.7) 144 (10.3) 49 (8.6)
2000-5000IU/day 258 (18.4) 204 (19.2) 233 (16.6) 84 (14.7)
5000+ IU/day 658 (47.0) 376 (35.3) 727 (51.9) 313 (54.6)
(Missing) (18 (1.3)) (28 (2.6) ∧) (19 (1.4)) (15 (2.6))
OMEGA 3 SUPPLEMENTATION
None 469 (33.5) 529 (49.7) 546 (39.0) 209 (36.5)
Fish oil only 469 (33.5) 312 (29.3) 355 (25.3) 94 (16.4)
Flaxseed only 145 (10.4) 55 (5.2) 274 (19.6) 167 (29.1)
Both marine and
plant-based omega-3
278 (19.8) 139 (13.1) 187 (13.4) 85 (14.8)
Other 40 (2.9) 30 (2.8) 39 (2.8) 18 (3.1)
MEDITATION
Never 592 (42.3) 477 (44.8) 532 (38) 175 (30.5)
<1 times/wk. 301 (21.5) 196 (18.4) 318 (22.7) 133 (23.2)
1–4 times/wk. 288 (20.6) 159 (14.9) 288 (20.6) 134 (23.4)
>5 times/wk. 148 (10.6) 82 (7.7) 169 (12.1) 73 (12.7)
(Missing) (72 (5.1)) (151 (14.2)∧) (94 (6.7)) (58 (10.1))
*Mean (standard deviation).
**Median (25th-75th percentile).
#The baseline characteristics that are associated with missingness at 2.5 year follow-up are highlighted in gray with ∧ indicating the variables that are associated with higher odds of
missingness at 2.5 year follow-up. For categorical variables, the reference category was taken as the first presented category in the table, and an arbitrary p-value cut-off of 0.05 was
used.
Frontiers in Neurology | www.frontiersin.org 12 December 2018 | Volume 9 | Article 1074
Weiland et al. HOLISM Longitudinal and Validation Cohorts
participated. Most participants consumed low to moderate
amounts of alcohol, were using vitamin D and/or omega-3
supplements, reported healthy diet, and most reported being
physically active to a moderate or high level.
Despite the positive health behavior reported by our
participants, nearly 40% were overweight or obese. While this is
lower than the numbers reported for the general population (90)
and for others with MS (91), these data are concerning given the
putative role of adiposity as a prognostic indicator in MS (92).
In terms of health outcomes, our cohort reported high rates
of morbidity and comorbidity, a pattern that is well-documented
for people with MS (93). Approximately half of the respondents
reported having at least one comorbidity on the SCQ, and the
high rate of clinically significant fatigue was in the range expected
for this population (94, 95). One fifth screened positive for
depression (PHQ-9); these are similar to findings of the large
NARCOMS cohort (96), and comparable to systematic review
findings (97). Five percent of our cohort reported moderate to
total visual impairment which is slightly lower than that reported
by NARCOMS participants with a similar time since diagnosis
(81, 98). Collectively, these findings have important implications
since physical and psychiatric comorbidities are important
determinants of disability progression (99, 100). Compared to
the NARCOMS study, our sample reported comparable levels of
disability given their time since diagnosis (81, 96). At a median
7.9 years since diagnosis, 12.6% of our sample reported severe
disability (bilateral support, wheelchair, or bedridden) compared
to 12% of the NARCOMS sample at 8 years post diagnosis (96).
For our sample this represented an increase of 60 participants
transitioning to the severe disability range over the 2.5 year
follow-up.
Validation Sample
Validation samples are useful tools to assess reproducibility
of findings and performance of prognostic models. Validation
processes have been extensively described (21, 22, 101, 102).
Our methodology, wherein participants were recruited via the
same methods as the HOLISM longitudinal study but lagged
temporally, provides us with the opportunity to investigate the
reproducibility of our findings from the original cohort, and to
use in validation of prediction models derived from the HOLISM
cohort.
A total of 573 new participants (reporting confirmed MS)
provided data in 2015 forming our validation sample. With some
exceptions, our data suggest that participants in the validation
sample were similar to those that comprise the HOLISM baseline
sample in terms of health outcomes and exposures. In most cases
differences observed were small, suggesting a reasonable level
of internal consistency with the HOLISM longitudinal sample
at baseline, which employed similar recruitment and sampling
methodology.
Compared to all main sample HOLISM baseline participants
described previously (14), the validation sample was comparable
in terms of age, sex and, level of education. Our validation
sample comprised a greater proportion of people residing in
Europe and Australasia and a lower proportion in North
America. Compared with HOLISM baseline data (14), the
validation sample comprised fewer participants with one or more
children (60 vs. 76%), slightly more engaged in full or part-
time employment (60 vs. 54%). Validation participants were
more likely to report having relapsing remitting MS compared
to the HOLISM main baseline sample (67 vs. 62%), but were
comparable in time since diagnosis.
For health outcomes, those in the validation sample were
more likely to rate their level of disability as normal/mild (60%)
compared to in the main HOLISM sample at baseline (54% (14).
The samples were comparable in terms of health-related QoL,
but not clinically significant fatigue and depression (PHQ-2) for
which the validation cohort was less affected (fatigue 54 vs. 66%;
depression risk, positive: 14 vs. 19%).
In terms of lifestyle, validation sample participants reported
data that were highly comparable to the HOLISM baseline in
dietary habits (53), social support, sun exposure, rate of smoking,
omega-3 and vitamin D supplementation (14).
In summary, our validation sample, employed similar
recruitment and sampling methodology, showed small
differences compared to the HOLISM longitudinal sample
at baseline. With its temporal separation from the HOLISM
cohort, our validation sample renders it suitable for use in
temporal or “narrow” validation methods of observations and
models derived from the HOLISM cohort. External validation
using samples recruited elsewhere and by different researchers
would further strengthen our confidence in the transportability
of HOLISM findings and any models derived from these data.
Strengths and Limitations
The HOLISM longitudinal study and validation cohort are
not without limitations. The data were self-reported and no
confirmation was possible using medical records given the
geographical locations of participants around the world. Hence, it
is possible that some participants self-reporting doctor-diagnosed
MS did not have MS. While self-reported diagnosis has been
shown to be valid in other MS cohorts (103), confirmation
of diagnoses through medical record checks for a subset
of participants from the HOLISM study would be valuable.
Measurement error, potentially leading to information bias may
therefore have impacted on the accuracy of some findings. Our
data may also have been biased by “panel conditioning,” wherein
respondents unconsciously change their responses to match
the anticipated goals of the research. The online recruitment
methodology may have biased our sample; previous research
has demonstrated that participants of online research are of
higher socioeconomic status. Our sample only includes English-
speaking participants, and those able to use a device on which
to complete the online survey. People with MS who have
significantly impaired vision, dexterity or cognitive ability were
thus less likely to have participated. Furthermore, the online
recruitment focussed mostly on websites, Facebook pages and
forums with a healthy lifestyle focus. Finally, the length of our
survey, at approximately 40min, may have been arduous for
some participants experiencing fatigue or significant disability.
We attempted to minimize this by enabling participants to save
their responses and re-enter the survey on separate occasions.
Participation bias is therefore a factor, further enhanced by those
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with healthier lifestyles being more likely to both participate and
complete follow-up. However, our data on a range of lifestyle,
sociodemographic and clinical covariates will enable us to control
for these biases to some extent but the results are unlikely to be
representative of all people diagnosed with MS.
For the HOLISM longitudinal cohort, we observed
appreciable attrition over the 2.5-year study duration (104).
In contrast to other studies we did not use incentives to
maximize retention. It is not possible to determine the degree
to which attrition was due to unwillingness to participate,
changes in contact information, or death given no information
is available on those lost to follow-up. Attrition was not random
and loss to follow-up may have further contributed to non-
representativeness in our cohort, which was already not a
random, or representative sample of people with MS at baseline.
Together, these limitations may result in biased estimates
and some associations may be less representative of the global
MS population. Due to high attrition and associated non-
representativeness, comparisons between subgroups within our
sample may be limited. While attrition has resulted in a
sample that is healthier and more highly educated, and may
reduce representativeness further, healthy volunteer bias is a
commonly documented limitation in longitudinal research. This
is likely to be further complicated by the lack of diversity of
participants recruited into cohort studies such as this wherein
the heterogeneity of people with MS is not fully represented.
This is seen in other MS cohorts such as NARCOMS which may
under-represent those with mild and severe impairments (96).
Interestingly, while selective recruitment into cohort studies can
impact baseline prevalence characteristics of the recruited sample
compared to the wider eligible population (105–107), simulation
studies (108) and empirical studies (109) indicate that such
baseline selectivity does not necessarily impact on the validity
of associations between baseline exposures and longitudinal
outcomes.
The prevalence of relapse-related symptoms at survey
completion was similar for the main sample at baseline and
the validation cohort (27 and 29%, respectively) (14). It is
conceivable that those experiencing a relapse may have reported
data that were not indicative of their usual health status,
instead reporting higher morbidity in health outcomes than
those not experiencing a relapse. Accordingly, we can consider
this covariate in the analysis to gauge what impact relapse-
associated symptomatology has, and potentially to undertake
sensitivity analyses restricted to those without such ongoing
relapse symptoms.
The HOLISM and validation cohorts have several strengths
that deserve acknowledgment. They are strengthened by the
wide exposure gradient apparent for lifestyle and demographics,
which will better enable associations to be identified. Further
comparison to other longitudinal datasets may provide further
confirmation of exposure gradients. The longitudinal nature
of the data may reveal “sleeper effects,” that is, those that
are detectable only over a long period of time, and which
may not be detectable in cross-sectional studies (110). The
number of variables collected, together with our large sample
size enable us to adjust for many potential confounders. We
recruited and retained participants from a broad range of
countries of birth and locations of residence. Finally, wherever
possible we used validated tools to minimize measurement
bias, many of which had been used previously for people
with MS.
CONCLUSIONS
Our HOLISM longitudinal data have substantial utility in
enabling the exploration of associations between a large range
of variables and, importantly, their change over time. Strategies
to account for bias due to high and selective attrition will be an
important consideration in future papers reporting on analyses
from this dataset. Our validation sample will allow us to replicate
exposure-outcome associations observed for our longitudinal
sample, and to undertake temporal validation of models derived
from HOLISM. Ultimately, identifying associations between
changes in health behavior and health outcomes over time
within participants, may lead to a better understanding of which
modifiable factors are associated with better health outcomes in
people with MS.
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